Pacira BioSciences, Inc. (PCRX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Pacira BioSciences reported revenue of $726.4M, up 4.2% from $697.2M the year before. Net income was $7.0M (a 1.0% net margin), or $0.16 per diluted share. Gross margin was 79.4% and operating margin was 2.6%. Operating activities generated $152.0M of cash, leaving $136.7M of free cash flow. At fiscal year end, Pacira BioSciences held $1.26B in total assets against $571.8M in total liabilities, including $158.5M of cash and equivalents.
Open the full interactive Pacira BioSciences financials → Quarterly statements, key ratios, valuation history and price charts.
Pacira BioSciences Key Stats
| Share Price | $36.31 |
|---|---|
| Market Cap | $1.46B |
| P/E Ratio | 226.9 |
| Revenue YoY Growth | +4.2% |
| 52-Week Range | $19.16 – $36.39 |
| Shares Outstanding | 39.5 million (basic, 2026 Q2) |
Pacira BioSciences Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $429.6M | $541.5M | $666.8M | $675.0M | $697.2M | $726.4M |
| Cost of Goods Sold | $383.3M | $451.6M | $606.8M | $587.3M | — | $707.2M |
| Gross Profit | $312.3M | $401.3M | $467.5M | $490.3M | $526.8M | $576.7M |
| Operating Income | $46.4M | $89.9M | $60.0M | $87.7M | -$73.4M | $19.2M |
| Pre-Tax Income | $20.1M | $56.4M | $13.3M | $61.7M | -$63.1M | $16.9M |
| Income Tax | -$125.4M | $14.4M | -$2.6M | $19.7M | $36.5M | $9.8M |
| Net Income | $145.5M | $42.0M | $15.9M | $42.0M | -$99.6M | $7.0M |
| Diluted EPS | $3.33 | $0.92 | $0.34 | $0.89 | -$2.15 | $0.16 |
Pacira BioSciences Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $179.5M | $196.9M | $177.4M | $192.4M |
| Net Income | $5.4M | $1.6M | $2.9M | $4.7M |
| Diluted EPS | $0.12 | $0.04 | $0.07 | $0.12 |
Pacira BioSciences Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $100.0M | $585.6M | $104.1M | $153.3M | $276.8M | $158.5M |
| Current Assets | $651.6M | $866.0M | $498.3M | $510.0M | $745.1M | $548.0M |
| Total Assets | $1.27B | $2.08B | $1.68B | $1.57B | $1.55B | $1.26B |
| Current Liabilities | $253.3M | $521.1M | $147.8M | $97.4M | $309.9M | $120.6M |
| Total Long-Term Debt | $462.7M | $1.05B | $689.5M | $522.4M | $585.3M | $372.2M |
| Total Liabilities | $654.8M | $1.34B | $906.2M | $704.3M | $775.2M | $571.8M |
| Shareholders' Equity | $619.7M | $730.4M | $775.0M | $870.1M | $778.3M | $693.1M |
Pacira BioSciences Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $77.0M | $125.7M | $145.3M | $154.6M | $189.4M | $152.0M |
| Cash From Investing | -$277.6M | -$20.8M | -$225.2M | $77.5M | -$83.3M | $99.5M |
| Cash From Financing | $222.3M | $380.7M | -$401.5M | -$183.0M | $17.4M | -$369.6M |
| Free Cash Flow | $39.2M | $79.9M | $115.2M | $139.5M | $178.8M | $136.7M |
Figures from Pacira BioSciences' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Pacira BioSciences financials page for every line item.
Pacira BioSciences Company Profile
| Ticker | PCRX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Brisbane, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001396814 |
Frequently Asked Questions
What was Pacira BioSciences' revenue in fiscal 2025?
Pacira BioSciences (PCRX) reported revenue of $726.4M for fiscal 2025.
What is Pacira BioSciences' annual revenue history?
Pacira BioSciences' annual revenue by fiscal year: 2020: $429.6M; 2021: $541.5M; 2022: $666.8M; 2023: $675.0M; 2024: $697.2M; 2025: $726.4M.
What was Pacira BioSciences' net income in fiscal 2025?
Pacira BioSciences reported net income of $7.0M for fiscal 2025.
What was Pacira BioSciences' earnings per share (EPS) in fiscal 2025?
Pacira BioSciences' diluted EPS was $0.16 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Pacira BioSciences generate in fiscal 2025?
Pacira BioSciences generated $136.7M of free cash flow in fiscal 2025.
What was Pacira BioSciences' revenue last quarter?
In its most recent reported quarter (2026 Q2), Pacira BioSciences reported revenue of $192.4M.
How much debt does Pacira BioSciences have?
Pacira BioSciences reported $372.2M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Pacira BioSciences are outstanding?
Pacira BioSciences reported a weighted average of 39.5 million basic shares outstanding in 2026 Q2.
What is Pacira BioSciences' market cap?
Based on its latest closing price, Pacira BioSciences (PCRX) has a market capitalization of about $1.46B.
When does Pacira BioSciences' fiscal year end?
Pacira BioSciences' fiscal year end, as registered with the SEC, is December 31.
Where is Pacira BioSciences headquartered?
Pacira BioSciences lists its business address in Brisbane, California in its SEC filings.